The objective of the Biostatistics and Data Management Core (Stats Core) of the Wisconsin Head and Neck Cancer SPORE, is to promote excellence in head and neck cancer translational research by providing dedicated and outstanding biostatistical consultation and collaborative support to the HN SPORE projects, Pathology Core, Administrative Core, and other investigators whose projects are supported under the Developmental Research and Career Development Programs. This support and collaboration will include laboratory and clinical-based research, focusing on translation from laboratory studies to clinical studies. With patient-derived xenografts that more closely reflect the biology of the original human cancer, the HN SPORE will open a new dimension in translational work. The Stats Core will achieve its objective by supporting investigators and providing statistical and data management expertise, thus enhancing the quality and ensuring the validity of the research undertaken in the HN SPORE. The Stats Core will provide statistical expertise in all stages of the research: from formulation of research questions through study experimental design, data collection and management, to data analysis, interpretation and dissemination of results through publications.
The Specific Aims of the Core are:
Aim 1. To collaborate with the HN SPORE investigators in the design of research studies, in analysis and interpretation of data, and in writing of scientific manuscripts disseminating the HN SPORE results to the scientific community.
Aim 2. To ensure the transparency and validity of statistical analysis via rigorous data collection and data management activities which include centralized management and standardization of the variety of data that arise from the HN SPORE projects; confidential and secure data archiving and data sharing; and validation and consistency check of collected data across HN SPORE projects.
Aim 3. To conduct, when necessary, methodology research to develop new statistical methods relevant to the individual projects.
The BioStatistics and Data Management Core will provide outstanding statistical and data analysis expertise to ensure that the Wisconsin Head and Neck SPORE can achieve its translational research goal of improving outcome for head and neck cancer patients.
| McDaniel, Nellie K; Cummings, Christopher T; Iida, Mari et al. (2018) MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Mol Cancer Ther 17:2297-2308 |
| Blitzer, Grace C; Rosenberg, Stephen A; Anderson, Bethany M et al. (2018) Results From 10 Years of a Free Oral Cancer Screening Clinic at a Major Academic Health Center. Int J Radiat Oncol Biol Phys 102:146-148 |
| Burr, Adam R; Harari, Paul M; Ko, Huaising C et al. (2018) HPV impacts survival of stage IVC non-oropharyngeal HNSCC cancer patients. Otorhinolaryngol Head Neck Surg 3: |
| Elsaid, Mohamed Y; Shahi, Ankita; Wang, Albert R et al. (2018) Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog. Mol Cancer Ther 17:2320-2328 |
| Jeong, Woo-Jin; Bu, Jiyoon; Kubiatowicz, Luke J et al. (2018) Peptide-nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms? Nano Converg 5:38 |
| Nyman, Patrick E; Buehler, Darya; Lambert, Paul F (2018) Loss of Function of Canonical Notch Signaling Drives Head and Neck Carcinogenesis. Clin Cancer Res 24:6308-6318 |
| Ko, Huaising C; Chen, Shuai; Wieland, Aaron M et al. (2017) Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database. Head Neck 39:2159-2170 |
| Werner, Lauryn R; Kler, Jasdeep S; Gressett, Monica M et al. (2017) Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma. Radiother Oncol 124:418-426 |
| Prabakaran, Prashanth J; Javaid, Amal M; Swick, Adam D et al. (2017) Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition. Clin Cancer Res 23:6044-6053 |
| Ko, Huaising C; Harari, Paul M; Chen, Shuai et al. (2017) Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx. JAMA Otolaryngol Head Neck Surg 143:1126-1133 |
Showing the most recent 10 out of 12 publications
